Bittersweet visit to @UniVerona DoS 🇮🇹 to participate in the dedication of a conference room in the name of my dear friend and former research fellow Fabio Bagante. You continue to live through the legacy of friendships that endure in all of us 🙏 #neverforgetyou
How to predict the risk of early recurrence in peri-hilar cholangiocarcinoma?
Try the Preoperative Recurrence Score!!!🕵️
4 easy-to-asses features:
1️⃣ size >18mm
2️⃣ suspected LN
3️⃣ HA involvement
4️⃣ PV involvement
🇮🇹 Cohort & 2 🇳🇱🇻🇦Validation Cohorts
👉 https://authors.elsevier.com/a/1jvwj2gGSo76HN
Great ILLS meeting Kyoto, sharing Liver Minimally Invasive surgery experiences and meet friends. @ILLS_LAPLIVER @HPBVerona @HopSTranCao
Surgery life
It's a wrap for the 4th edition of our hands-on course on Robotic HPB surgery.
🧑⚕️A faculty with experts from 3 highly experienced centers.
🎮Hands-on practice on simulator and animal model.
📽 Live surgery.
Tutoring and Mentoring as means to progress with innovation in surgery!
🔎 Check out our last paper on Percutaneous Ablation in Perivascular-HCC
👎 Not for all lesions, only not suitable for 🔪
👌 Less than 2 cm
👍 in proximity to smaller vessels (<5mm)
🤔 Glissoneal better than the Hepatic vein?
https://doi.org/10.1016/j.crad.2024.05.012
🔢How many subtypes of intrahepatic cholangiocarcinoma do you know?
👩🔬Multi-omics analyses help answer the question.
🥼What about the clinical characteristics?
Check out the Systematic Review from our team at @HPBVerona @ARuzzenente
🔎
Is Total Neoadjuvant Therapy better for locally advanced rectal cancer?
Check out our new Systematic Review and Meta-Analysis.
- 2⃣7⃣ RCTs!
- 📈increased complete pathological response!
- 👍good tolerability and operative outcomes!
A new first-line treatment?
Portal stenting in recurrent or locally advanced pCCA!
- Safe & Feasible (💯% success rate!, 13% overall complications) 💪
- Improves QoL 🆙 and allows patients to get Chemo! 💊
Check out our paper on EJSO DOI: 10.1016/j.ejso.2024.107984
@UniVerona #HPB #liversurgery #pcca